{"transactions":[{"id":4634003,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-03T00:43:41.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":1775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1775,"derivative":{"exercise_price":106.94,"expiration_date":"2036-10-01","underlying":"Common Stock","underlying_shares":1775},"source":{"system":"sec-edgar","filing":"0001159036-26-000136","document":"wk-form4_1790973818.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000136/wk-form4_1790973818.xml","form_type":"4"}},{"id":4634002,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-10-03T00:43:41.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":1169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the\ndate of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1169,"source":{"system":"sec-edgar","filing":"0001159036-26-000136","document":"wk-form4_1790973818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000136/wk-form4_1790973818.xml","form_type":"4"}},{"id":708343,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-16T20:28:34.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":151,"price":82.62,"value":12475.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant."}],"balance_after":3390,"source":{"system":"sec-edgar","filing":"0001061983-26-000078","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000078/form4.xml","form_type":"4"}},{"id":732516,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:16:45.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":766,"derivative":{"exercise_price":499.86,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":766},"source":{"system":"sec-edgar","filing":"0001628280-26-044307","document":"wk-form4_1781813798.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026044307/wk-form4_1781813798.xml","form_type":"4"}},{"id":732515,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:16:45.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":3081,"source":{"system":"sec-edgar","filing":"0001628280-26-044307","document":"wk-form4_1781813798.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026044307/wk-form4_1781813798.xml","form_type":"4"}},{"id":757688,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-01T22:00:05.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":9311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended."}],"balance_after":9311,"derivative":{"underlying":"Common Stock","underlying_shares":9311},"source":{"system":"sec-edgar","filing":"0001560782-26-000002","document":"form4-06012026_060601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000156078226000002/form4-06012026_060601.xml","form_type":"4"}},{"id":757687,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options (Right to Buy)","published_at":"2026-06-01T22:00:05.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":16004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders."}],"balance_after":16004,"derivative":{"exercise_price":21.66,"expiration_date":"2036-05-28","underlying":"Common Stock","underlying_shares":16004},"source":{"system":"sec-edgar","filing":"0001560782-26-000002","document":"form4-06012026_060601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000156078226000002/form4-06012026_060601.xml","form_type":"4"}},{"id":757686,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-01T22:00:05.000Z","date":"2026-05-29","kind":"exercise","planned":false,"acquired":false,"shares":8107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8107},"source":{"system":"sec-edgar","filing":"0001560782-26-000002","document":"form4-06012026_060601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000156078226000002/form4-06012026_060601.xml","form_type":"4"}},{"id":757685,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T22:00:05.000Z","date":"2026-05-29","kind":"exercise","planned":false,"acquired":true,"shares":8107,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."}],"balance_after":12148,"source":{"system":"sec-edgar","filing":"0001560782-26-000002","document":"form4-06012026_060601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000156078226000002/form4-06012026_060601.xml","form_type":"4"}},{"id":762483,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2026-05-27T23:14:59.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":4301,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4301,"derivative":{"exercise_price":77.15,"exercise_date":"2026-06-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":4301},"source":{"system":"sec-edgar","filing":"0001061983-26-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000061/form4.xml","form_type":"4"}},{"id":762482,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-27T23:14:59.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3239,"source":{"system":"sec-edgar","filing":"0001061983-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000061/form4.xml","form_type":"4"}},{"id":808341,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-04-15T22:32:13.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":191,"price":65.37,"value":12485.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested."}],"balance_after":388,"source":{"system":"sec-edgar","filing":"0001061983-26-000037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000037/form4.xml","form_type":"4"}},{"id":935901,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-20T21:17:27.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":197,"price":63.44,"value":12497.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of Issuer's Board of Directors."}],"balance_after":197,"source":{"system":"sec-edgar","filing":"0001061983-26-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000010/form4.xml","form_type":"4"}},{"id":1002683,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T23:00:04.000Z","date":"2025-11-10","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":22.3661,"value":670983.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":4041,"source":{"system":"sec-edgar","filing":"0001560782-25-000006","document":"form4-11122025_061101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000156078225000006/form4-11122025_061101.xml","form_type":"4"}},{"id":1060635,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2025-08-20T12:04:20.000Z","date":"2025-08-19","kind":"grant","planned":false,"acquired":true,"shares":27450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Initial Grant to New Director."}],"balance_after":27450,"derivative":{"exercise_price":37.84,"exercise_date":"2025-09-19","expiration_date":"2035-08-19","underlying":"Common Stock","underlying_shares":27450},"source":{"system":"sec-edgar","filing":"0001127602-25-020750","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225020750/form4.xml","form_type":"4"}},{"id":1102928,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T20:34:25.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":1290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date."}],"balance_after":1290,"derivative":{"exercise_price":285.73,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":1290},"source":{"system":"sec-edgar","filing":"0001628280-25-032850","document":"wk-form4_1750797254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025032850/wk-form4_1750797254.xml","form_type":"4"}},{"id":1102927,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T20:34:25.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":2627,"source":{"system":"sec-edgar","filing":"0001628280-25-032850","document":"wk-form4_1750797254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025032850/wk-form4_1750797254.xml","form_type":"4"}},{"id":1128192,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-02T22:05:06.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":8107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders."}],"balance_after":8107,"derivative":{"underlying":"Common Stock","underlying_shares":8107},"source":{"system":"sec-edgar","filing":"0001415889-25-015271","document":"form4-06022025_060603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588925015271/form4-06022025_060603.xml","form_type":"4"}},{"id":1128191,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options (Right to Buy)","published_at":"2025-06-02T22:05:06.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":13793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders."}],"balance_after":13793,"derivative":{"exercise_price":22.29,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":13793},"source":{"system":"sec-edgar","filing":"0001415889-25-015271","document":"form4-06022025_060603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588925015271/form4-06022025_060603.xml","form_type":"4"}},{"id":1128190,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-02T22:05:06.000Z","date":"2025-05-29","kind":"exercise","planned":false,"acquired":false,"shares":9387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9387},"source":{"system":"sec-edgar","filing":"0001415889-25-015271","document":"form4-06022025_060603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588925015271/form4-06022025_060603.xml","form_type":"4"}},{"id":1128189,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:05:06.000Z","date":"2025-05-29","kind":"exercise","planned":false,"acquired":true,"shares":9387,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."}],"balance_after":34041,"source":{"system":"sec-edgar","filing":"0001415889-25-015271","document":"form4-06022025_060603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588925015271/form4-06022025_060603.xml","form_type":"4"}},{"id":1238959,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T21:31:10.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":111.06,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-25-009079","document":"wk-form4_1740778263.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009079/wk-form4_1740778263.xml","form_type":"4"}},{"id":1238958,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T21:31:10.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":9470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":65.06,"expiration_date":"2025-06-16","underlying":"Common Stock","underlying_shares":9470},"source":{"system":"sec-edgar","filing":"0001628280-25-009079","document":"wk-form4_1740778263.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009079/wk-form4_1740778263.xml","form_type":"4"}},{"id":1238957,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:31:10.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":770,"price":348.9433,"value":268686.341,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.73 to $349.705, inclusive."}],"balance_after":1912,"source":{"system":"sec-edgar","filing":"0001628280-25-009079","document":"wk-form4_1740778263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009079/wk-form4_1740778263.xml","form_type":"4"}},{"id":1238956,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:31:10.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":14302,"price":347.39,"value":4968371.78,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.36 to $348.225, inclusive."}],"balance_after":2682,"source":{"system":"sec-edgar","filing":"0001628280-25-009079","document":"wk-form4_1740778263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009079/wk-form4_1740778263.xml","form_type":"4"}},{"id":1238955,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:31:10.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":398,"price":346.9031,"value":138067.4338,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.34 to $347.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":16984,"source":{"system":"sec-edgar","filing":"0001628280-25-009079","document":"wk-form4_1740778263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009079/wk-form4_1740778263.xml","form_type":"4"}},{"id":1238954,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:31:10.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":6000,"price":111.06,"value":666360.0,"ownership":{"direct":true},"balance_after":17382,"source":{"system":"sec-edgar","filing":"0001628280-25-009079","document":"wk-form4_1740778263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009079/wk-form4_1740778263.xml","form_type":"4"}},{"id":1238953,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:31:10.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":9470,"price":65.06,"value":616118.2,"ownership":{"direct":true},"balance_after":11382,"source":{"system":"sec-edgar","filing":"0001628280-25-009079","document":"wk-form4_1740778263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009079/wk-form4_1740778263.xml","form_type":"4"}},{"id":1468298,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T01:42:15.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":1105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date."}],"balance_after":1105,"derivative":{"exercise_price":280.04,"expiration_date":"2031-06-25","underlying":"Common Stock","underlying_shares":1105},"source":{"system":"sec-edgar","filing":"0000950170-24-078750","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024078750/ownership.xml","form_type":"4"}},{"id":1468297,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-28T01:42:15.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":1912,"source":{"system":"sec-edgar","filing":"0000950170-24-078750","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024078750/ownership.xml","form_type":"4"}},{"id":1497024,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-31T22:00:16.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":9387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders."}],"balance_after":9387,"derivative":{"underlying":"Common Stock","underlying_shares":9387},"source":{"system":"sec-edgar","filing":"0001415889-24-015087","document":"form4-05312024_060512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588924015087/form4-05312024_060512.xml","form_type":"4"}},{"id":1497023,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options (Right to Buy)","published_at":"2024-05-31T22:00:16.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":15959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders."}],"balance_after":15959,"derivative":{"exercise_price":14.62,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":15959},"source":{"system":"sec-edgar","filing":"0001415889-24-015087","document":"form4-05312024_060512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588924015087/form4-05312024_060512.xml","form_type":"4"}},{"id":1497022,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-31T22:00:16.000Z","date":"2024-05-29","kind":"exercise","planned":false,"acquired":false,"shares":6652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6652},"source":{"system":"sec-edgar","filing":"0001415889-24-015087","document":"form4-05312024_060512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588924015087/form4-05312024_060512.xml","form_type":"4"}},{"id":1497021,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T22:00:16.000Z","date":"2024-05-29","kind":"exercise","planned":false,"acquired":true,"shares":6652,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."}],"balance_after":24654,"source":{"system":"sec-edgar","filing":"0001415889-24-015087","document":"form4-05312024_060512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588924015087/form4-05312024_060512.xml","form_type":"4"}},{"id":1550599,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"exercise","planned":true,"acquired":false,"shares":10912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":105.08,"expiration_date":"2024-06-17","underlying":"Common Stock","underlying_shares":10912},"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550598,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":1577,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":10912,"derivative":{"exercise_price":105.08,"expiration_date":"2024-06-17","underlying":"Common Stock","underlying_shares":1577},"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550597,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":100.45,"expiration_date":"2024-06-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550596,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":200,"price":248.4508,"value":49690.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.96 to $248.72, inclusive."}],"balance_after":1198,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550595,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":43,"price":247.0342,"value":10622.4706,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.72 to $247.24, inclusive."}],"balance_after":1398,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550594,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":557,"price":246.2958,"value":137186.7606,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.72 to $247.24, inclusive."}],"balance_after":1441,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550593,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":2991,"price":244.8946,"value":732479.7486,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.62 to $246.54, inclusive."}],"balance_after":1998,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550592,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":6279,"price":244.1927,"value":1533285.9633,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.61 to $245.53, inclusive."}],"balance_after":4989,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550591,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":842,"price":243.2559,"value":204821.4678,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.60 to $244.58, inclusive."}],"balance_after":11268,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550590,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-02","kind":"exercise","planned":true,"acquired":true,"shares":10912,"price":105.08,"value":1146632.96,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.58 to $243.56, inclusive."}],"balance_after":12110,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550589,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":274,"price":266.9052,"value":73132.0248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.73 to $267.21, inclusive."}],"balance_after":1198,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550588,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":500,"price":265.486,"value":132743.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.35 to $265.64, inclusive."}],"balance_after":1472,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550587,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":351,"price":264.8908,"value":92976.6708,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.11 to $265.07, inclusive."}],"balance_after":1972,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550586,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":178,"price":263.3133,"value":46869.7674,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.09 to $264.07, inclusive."}],"balance_after":2323,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550585,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":800,"price":262.005,"value":209604.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.59 to $262.15, inclusive."}],"balance_after":2501,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550584,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":200,"price":259.11,"value":51822.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.10 to $259.12, inclusive."}],"balance_after":3301,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550583,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":1460,"price":258.2834,"value":377093.764,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.01 to $258.93, inclusive."}],"balance_after":3501,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550582,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":3604,"price":257.2981,"value":927302.3524,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.01 to $258.00, inclusive."}],"balance_after":4961,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550581,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":7401,"price":256.5019,"value":1898370.5619,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.01 to $257.00, inclusive."}],"balance_after":8565,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550580,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":6809,"price":255.6366,"value":1740629.6094,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.01 to $256.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":15966,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550579,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":1577,"price":105.08,"value":165711.16,"ownership":{"direct":true},"balance_after":22775,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1550578,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:41:46.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":100.45,"value":2009000.0,"ownership":{"direct":true},"balance_after":21198,"source":{"system":"sec-edgar","filing":"0000899243-24-000243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000243/doc4.xml","form_type":"4"}},{"id":1807558,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-15T20:04:28.000Z","date":"2023-08-14","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":43.741,"value":437410.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.54 to $44.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20503,"source":{"system":"sec-edgar","filing":"0001415889-23-012257","document":"form4-08152023_080821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923012257/form4-08152023_080821.xml","form_type":"4"}},{"id":1807557,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-15T20:04:28.000Z","date":"2023-08-11","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":43.711,"value":437110.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.63 to $43.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30503,"source":{"system":"sec-edgar","filing":"0001415889-23-012257","document":"form4-08152023_080821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923012257/form4-08152023_080821.xml","form_type":"4"}},{"id":1850115,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T22:41:25.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":1198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest on June 15, 2024, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":1198,"source":{"system":"sec-edgar","filing":"0000899243-23-016057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323016057/doc4.xml","form_type":"4"}},{"id":1867889,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-06T01:38:09.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":6652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":6652,"derivative":{"underlying":"Common Stock","underlying_shares":6652},"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1867888,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options (Right to Buy)","published_at":"2023-06-06T01:38:09.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":11045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":11045,"derivative":{"exercise_price":23.9,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":11045},"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1867887,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-06T01:38:09.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":false,"shares":8552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8552},"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1867886,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-06T01:38:09.000Z","date":"2022-06-07","kind":"exercise","planned":false,"acquired":false,"shares":6391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6391},"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1867885,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-06T01:38:09.000Z","date":"2021-06-22","kind":"exercise","planned":false,"acquired":false,"shares":3059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3059},"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1867884,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-06T01:38:09.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":true,"shares":8552,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."}],"balance_after":18002,"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1867883,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-06T01:38:09.000Z","date":"2022-06-07","kind":"exercise","planned":false,"acquired":true,"shares":6391,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."}],"balance_after":9450,"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1867882,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-06T01:38:09.000Z","date":"2021-06-22","kind":"exercise","planned":false,"acquired":true,"shares":3059,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."}],"balance_after":3059,"source":{"system":"sec-edgar","filing":"0001209191-23-034695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919123034695/doc4.xml","form_type":"4"}},{"id":1899764,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-05-09T22:14:01.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":11371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":11371,"derivative":{"exercise_price":31,"exercise_date":"2024-05-05","expiration_date":"2033-05-05","underlying":"Common Stock","underlying_shares":11371},"source":{"system":"sec-edgar","filing":"0001415889-23-007689","document":"form4-05092023_100552.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007689/form4-05092023_100552.xml","form_type":"4"}},{"id":1899763,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-09T22:14:01.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":8065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.   Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":40503,"source":{"system":"sec-edgar","filing":"0001415889-23-007689","document":"form4-05092023_100552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007689/form4-05092023_100552.xml","form_type":"4"}},{"id":2061936,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T13:12:48.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":60414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date."}],"balance_after":109873,"source":{"system":"sec-edgar","filing":"0001628280-23-000422","document":"wf-form4_167294235465620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023000422/wf-form4_167294235465620.xml","form_type":"4"}},{"id":2167211,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-02T10:30:00.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":35082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on September 1, 2023, the one-year anniversary of the grant date."}],"balance_after":49459,"source":{"system":"sec-edgar","filing":"0001628280-22-024219","document":"wf-form4_166212898622803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022024219/wf-form4_166212898622803.xml","form_type":"4"}},{"id":2225840,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-21T10:30:13.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":9470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date."}],"balance_after":9470,"derivative":{"exercise_price":65.06,"expiration_date":"2025-06-16","underlying":"Common Stock","underlying_shares":9470},"source":{"system":"sec-edgar","filing":"0000899243-22-023230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322023230/doc4.xml","form_type":"4"}},{"id":2229631,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T14:46:44.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":1.11,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-22-017338","document":"wf-form4_165540519195576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022017338/wf-form4_165540519195576.xml","form_type":"4"}},{"id":2238138,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-10T00:30:32.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":8552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Acadia common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":8552,"derivative":{"underlying":"Common Stock","underlying_shares":8552},"source":{"system":"sec-edgar","filing":"0001209191-22-035668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919122035668/doc4.xml","form_type":"4"}},{"id":2238137,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options (Right to Buy)","published_at":"2022-06-10T00:30:32.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":14368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":14368,"derivative":{"exercise_price":18.27,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":14368},"source":{"system":"sec-edgar","filing":"0001209191-22-035668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919122035668/doc4.xml","form_type":"4"}},{"id":2279549,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-07T00:05:30.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":6206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":32438,"source":{"system":"sec-edgar","filing":"0001179110-22-002908","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022002908/edgar.xml","form_type":"4"}},{"id":2441122,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-01-06T09:39:13.000Z","date":"2022-01-04","kind":"exercise","acquired":false,"shares":809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs granted on July 1, 2021 vest in full on January 4, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs granted on July 1, 2021 vest in full on January 4, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":809},"source":{"system":"sec-edgar","filing":"0001628280-22-000412","document":"wf-form4_164147994091373.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022000412/wf-form4_164147994091373.xml","form_type":"4"}},{"id":2441121,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-01-06T09:39:13.000Z","date":"2022-01-04","kind":"exercise","acquired":false,"shares":13568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13568},"source":{"system":"sec-edgar","filing":"0001628280-22-000412","document":"wf-form4_164147994091373.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022000412/wf-form4_164147994091373.xml","form_type":"4"}},{"id":2441120,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T09:39:13.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."}],"balance_after":14377,"source":{"system":"sec-edgar","filing":"0001628280-22-000412","document":"wf-form4_164147994091373.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022000412/wf-form4_164147994091373.xml","form_type":"4"}},{"id":2441119,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T09:39:13.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":13568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."}],"balance_after":13568,"source":{"system":"sec-edgar","filing":"0001628280-22-000412","document":"wf-form4_164147994091373.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022000412/wf-form4_164147994091373.xml","form_type":"4"}},{"id":2639151,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-07T20:23:30.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6500,"derivative":{"exercise_price":3.05,"exercise_date":"2022-06-15","expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001209191-21-045940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000120919121045940/doc4.xml","form_type":"4"}},{"id":2640723,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-07-06T20:28:28.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":809,"derivative":{"exercise_date":"2022-01-04","expiration_date":"2022-01-04","underlying":"Common Stock","underlying_shares":809},"source":{"system":"sec-edgar","filing":"0001209191-21-045705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000120919121045705/doc4.xml","form_type":"4"}},{"id":2656308,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-24T20:39:24.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":6391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":6391,"derivative":{"underlying":"Common Stock","underlying_shares":6391},"source":{"system":"sec-edgar","filing":"0001209191-21-043037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121043037/doc4.xml","form_type":"4"}},{"id":2656307,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options (Right to Buy)","published_at":"2021-06-24T20:39:24.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":11637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":11637,"derivative":{"exercise_price":24.88,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":11637},"source":{"system":"sec-edgar","filing":"0001209191-21-043037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121043037/doc4.xml","form_type":"4"}},{"id":2661593,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T12:03:52.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":12489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date."}],"balance_after":12489,"derivative":{"exercise_price":105.08,"expiration_date":"2024-06-17","underlying":"Common Stock","underlying_shares":12489},"source":{"system":"sec-edgar","filing":"0000899243-21-024669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321024669/doc4.xml","form_type":"4"}},{"id":2725295,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-05-07T00:01:50.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":5230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":26232,"source":{"system":"sec-edgar","filing":"0001179110-21-004971","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911021004971/edgar.xml","form_type":"4"}},{"id":2919448,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-01-05T18:32:19.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":13568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full upon the one year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full upon the one year anniversary of the date of grant."}],"balance_after":13568,"derivative":{"underlying":"Common Stock","underlying_shares":13568},"source":{"system":"sec-edgar","filing":"0001628280-21-000090","document":"wf-form4_160988952610822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828021000090/wf-form4_160988952610822.xml","form_type":"4"}},{"id":2966408,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-25T23:57:54.000Z","date":"2020-11-25","kind":"sale","acquired":false,"shares":10363,"price":40.413,"value":418799.919,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share.  These shares were sold at prices ranging from $40.40 to $40.48.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21002,"source":{"system":"sec-edgar","filing":"0001179110-20-011427","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020011427/edgar.xml","form_type":"4"}},{"id":3058887,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T22:43:44.000Z","date":"2020-08-13","kind":"sale","acquired":false,"shares":34337,"price":29.12,"value":999893.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average sales price per share.  These shares were sold at prices ranging from $29.00 to $29.37.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31365,"source":{"system":"sec-edgar","filing":"0001179110-20-009018","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020009018/edgar.xml","form_type":"4"}},{"id":3100125,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-25T22:00:11.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":3059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":3059,"derivative":{"underlying":"Common Stock","underlying_shares":3059},"source":{"system":"sec-edgar","filing":"0001209191-20-038977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120038977/doc4.xml","form_type":"4"}},{"id":3100124,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Options (Right to Buy)","published_at":"2020-06-25T22:00:11.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":5579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date."}],"balance_after":5579,"derivative":{"exercise_price":52.73,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":5579},"source":{"system":"sec-edgar","filing":"0001209191-20-038977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120038977/doc4.xml","form_type":"4"}},{"id":3105754,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-18T11:53:32.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date."}],"balance_after":6000,"derivative":{"exercise_price":111.06,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-20-016992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320016992/doc4.xml","form_type":"4"}},{"id":3108581,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-16T16:52:39.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date."}],"balance_after":6500,"derivative":{"exercise_price":8.42,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001628280-20-009551","document":"wf-form4_159234074046391.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828020009551/wf-form4_159234074046391.xml","form_type":"4"}},{"id":3151316,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-13T22:00:11.000Z","date":"2020-05-11","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":27.25,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-028940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120028940/doc4.xml","form_type":"4"}},{"id":3151315,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-13T22:00:11.000Z","date":"2020-05-11","kind":"exercise","acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant."}],"balance_after":11250,"derivative":{"exercise_price":25.24,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001209191-20-028940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120028940/doc4.xml","form_type":"4"}},{"id":3151314,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T22:00:11.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":26250,"price":51.1306,"value":1342178.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.975 to $51.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-028940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120028940/doc4.xml","form_type":"4"}},{"id":3151313,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T22:00:11.000Z","date":"2020-05-11","kind":"exercise","acquired":true,"shares":15000,"price":27.25,"value":408750.0,"ownership":{"direct":true},"balance_after":26250,"source":{"system":"sec-edgar","filing":"0001209191-20-028940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120028940/doc4.xml","form_type":"4"}},{"id":3151312,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T22:00:11.000Z","date":"2020-05-11","kind":"exercise","acquired":true,"shares":11250,"price":25.24,"value":283950.0,"ownership":{"direct":true},"balance_after":11250,"source":{"system":"sec-edgar","filing":"0001209191-20-028940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120028940/doc4.xml","form_type":"4"}},{"id":3165557,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T23:11:18.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":8829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":65702,"source":{"system":"sec-edgar","filing":"0001179110-20-005377","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020005377/edgar.xml","form_type":"4"}},{"id":3417824,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-11T23:18:15.000Z","date":"2019-09-09","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.52,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-049230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119049230/doc4.xml","form_type":"4"}}],"next_cursor":"2019-09-11T23:18:15.000000Z,3417824"}